Abstract
ObjectiveEvidence on recurrence patterns after bevacizumab in epithelial ovarian cancer is still insufficient. The aim of this study was to evaluate recurrence patterns after treatment with bevacizumab as second-line treatment...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have